Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria Policlinico, Modena, Italy.
Gynecol Endocrinol. 2022 Jan;38(1):63-67. doi: 10.1080/09513590.2021.1991909. Epub 2021 Oct 16.
The beneficial effects of Vitamin D (VD) and Epigallocatechin gallate (EGCG), a polyphenol of green tea, on the growth of uterine fibroids (UF) were previously described and . We have decided to investigate their simultaneous administration in women with UFs in late reproductive life.
40 years old = 16 premenopausal women with intramural (IM) or subserosal (SS) UF of ≥3 cm or several UFs of different sizes, even smaller but with a total diameter ≥3 cm but <10 cm, without further concomitant organic causes of abnormal uterine bleeding, treated with EGCG 300 mg, Vitamin B6 10 mg and VD 50 µg/day for 90 days. Women completed a diary on a daily basis to obtain information about bleeding and pelvic pain.
We have observed a significant reduction in UF's mean size both at patient's (-17.8%, = .03) and at single UF's level (-37.3%, = .015). The effect was more evident in women with predominant IM ( = .016) in comparison to SS UFs. No significant changes were observed for uterine and ovarian volume and endometrial thickness during treatment. We reported a significant decrease in menstrual flow length of 0.9 day ( = .04) with no modification in cycle length, menstrual flow intensity and menstrual pain intensity. The satisfaction with treatment was in general very high, with no adverse effects reported.
The concomitant administration of VD and EGCG represents a promising treatment of UF in women of late reproductive life for which hormonal manipulation is not foreseen.
先前已有研究描述了维生素 D（VD）和表没食子儿茶素没食子酸酯（EGCG），即绿茶中的一种多酚，对子宫肌瘤（UF）生长的有益影响。我们决定研究同时在生育后期患有 UF 的女性中使用它们。
≥40 岁的 16 名绝经前妇女患有≥3cm 的子宫壁内（IM）或子宫浆膜下（SS）UF 或多个不同大小的 UF，即使较小但总直径≥3cm 但 <10cm，且无其他导致异常子宫出血的伴随有机原因，接受 EGCG 300mg、维生素 B6 10mg 和 VD 50μg/天治疗 90 天。妇女每天填写日记以获取出血和盆腔疼痛的信息。
我们观察到 UF 的平均大小在患者（-17.8%，=0.03）和单个 UF 水平（-37.3%，=0.015）都有显著降低。在以 IM 为主的妇女中（=0.016），效果更为明显，与 SS UF 相比。在治疗期间，子宫和卵巢体积以及子宫内膜厚度没有观察到显著变化。我们报告了月经流量长度的显著减少 0.9 天（=0.04），而周期长度、月经流量强度和月经疼痛强度没有改变。总的来说，治疗的满意度非常高，没有报告不良反应。
VD 和 EGCG 的同时给药为生育后期不打算进行激素治疗的 UF 妇女提供了一种有前景的治疗方法。
